Standout Papers

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001... 2013 2026 2017 2021 445
  1. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study (2013)
    Takashi Seto, Katsuyuki Kiura et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 9 from Science/Nature 76 standout
Sub-graph 1 of 19

Citing Papers

Cancer statistics, 2022
2022 Standout
Cancer Statistics, 2021
2021 Standout
1 intermediate paper

Works of Masao Harada being referenced

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
2014
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
2013 Standout

Author Peers

Author Last Decade Papers Cites
Masao Harada 1782 1852 670 69 2.5k
Michael S. Rabin 1872 2210 641 86 3.2k
Alejandro Navarro 1935 1257 650 107 2.5k
G Dabouis 1456 1522 451 66 2.2k
Katsuhiro Masago 1156 1491 444 114 2.0k
Joo Hang Kim 1825 1818 775 89 3.0k
Giovanni Selvaggi 2237 1563 965 75 3.2k
Hira Rizvi 2766 1639 657 64 3.4k
Joshua K. Sabari 2084 1319 957 82 2.9k
Ticiana Leal 2410 1452 737 97 3.1k
Toshiyuki Kozuki 1976 1758 712 113 2.9k

All Works

Loading papers...

Rankless by CCL
2026